Michael J. Hanley

3.9k total citations · 1 hit paper
110 papers, 2.5k citations indexed

About

Michael J. Hanley is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Michael J. Hanley has authored 110 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 32 papers in Hematology and 29 papers in Genetics. Recurrent topics in Michael J. Hanley's work include Chronic Lymphocytic Leukemia Research (28 papers), Multiple Myeloma Research and Treatments (20 papers) and Protein Degradation and Inhibitors (12 papers). Michael J. Hanley is often cited by papers focused on Chronic Lymphocytic Leukemia Research (28 papers), Multiple Myeloma Research and Treatments (20 papers) and Protein Degradation and Inhibitors (12 papers). Michael J. Hanley collaborates with scholars based in United States, Japan and Canada. Michael J. Hanley's co-authors include David J. Greenblatt, Nicholas M. P. King, Neeraj Gupta, Karthik Venkatakrishnan, Karen Davidson, Paul Cancalon, Wilbur Widmer, Patrick O’Neill, Juha P. Kokko and Michael H. Court and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael J. Hanley

104 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

2010 557 citations Michael J. Hanley, Nicholas M. P. King et al. Clinical Pharmacokinetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael J. Hanley United States	25	667	424	421	320	315	110	2.5k
Vladimír Palička Czechia	28	708 1.1×	434 1.0×	268 0.6×	359 1.1×	158 0.5×	217	3.4k
Frieder Keller Germany	29	333 0.5×	431 1.0×	418 1.0×	246 0.8×	191 0.6×	160	2.8k
Zoltán Endre Australia	40	1.0k 1.5×	1.2k 2.9×	627 1.5×	232 0.7×	294 0.9×	191	6.5k
Elizabeth J. Murphy United States	31	699 1.0×	385 0.9×	153 0.4×	373 1.2×	103 0.3×	72	3.3k
Sebastian Harder Germany	34	402 0.6×	549 1.3×	214 0.5×	422 1.3×	462 1.5×	109	3.5k
Otto Bekers Netherlands	31	459 0.7×	412 1.0×	496 1.2×	239 0.7×	74 0.2×	139	3.1k
Marc Pfister Switzerland	33	922 1.4×	939 2.2×	418 1.0×	250 0.8×	157 0.5×	184	3.9k
Steven M. Belknap United States	22	206 0.3×	505 1.2×	295 0.7×	271 0.8×	207 0.7×	60	2.4k
Timothy R. Morgan United States	54	1.2k 1.8×	976 2.3×	336 0.8×	588 1.8×	210 0.7×	207	12.4k
Eberhard Wieland Germany	38	1.2k 1.8×	911 2.1×	190 0.5×	364 1.1×	214 0.7×	132	4.6k

Countries citing papers authored by Michael J. Hanley

Since Specialization

Citations

This map shows the geographic impact of Michael J. Hanley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Hanley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Hanley more than expected).

Fields of papers citing papers by Michael J. Hanley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Hanley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Hanley. The network helps show where Michael J. Hanley may publish in the future.

Co-authorship network of co-authors of Michael J. Hanley

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Hanley. A scholar is included among the top collaborators of Michael J. Hanley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Hanley. Michael J. Hanley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verstockt, Bram, et al.. (2025). P0069 TP-317, a Novel BLT1 Agonist Oral Therapy for Inflammatory Bowel Disease, Exhibits Anti-Inflammatory and Epithelial Barrier Protective Efficacy in Murine DSS Colitis and TNFΔARE Ileitis. Journal of Crohn s and Colitis. 19(Supplement_1). i433–i433.

Hanley, Michael J., Steven Zhang, Robert Griffin, et al.. (2024). A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational New Drugs. 42(4). 343–352. 3 indexed citations

Hanley, Michael J., Karen Rowland Yeo, Meera Tugnait, et al.. (2024). Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach. CPT Pharmacometrics & Systems Pharmacology. 13(4). 624–637. 2 indexed citations

Hanley, Michael J., Paul M. Diderichsen, Benjamin E. Rich, et al.. (2023). Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study. Clinical Pharmacology & Therapeutics. 114(2). 413–422. 6 indexed citations

Hanley, Michael J., David Kerstein, Meera Tugnait, et al.. (2023). Brigatinib pharmacokinetics in patients with chronic hepatic impairment. Investigational New Drugs. 41(3). 402–410. 3 indexed citations

Gupta, Neeraj, Karen L. Reckamp, David Ross Camidge, et al.. (2022). Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC. Clinical and Translational Science. 15(5). 1143–1154. 5 indexed citations

Hanley, Michael J., M. D’Arcangelo, Enriqueta Felip, et al.. (2022). A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors. The Journal of Clinical Pharmacology. 63(5). 583–592. 2 indexed citations

Gupta, Neeraj, Michael J. Hanley, David Kerstein, et al.. (2021). Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational New Drugs. 39(5). 1306–1314. 7 indexed citations

Gupta, Neeraj, Xiaohui Wang, Elliot Offman, et al.. (2020). Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical Pharmacokinetics. 60(2). 235–247. 15 indexed citations

10.

Gupta, Neeraj, Michael J. Hanley, Cindy Q. Xia, et al.. (2018). Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clinical Pharmacokinetics. 58(4). 431–449. 52 indexed citations

11.

Gupta, Neeraj, Michael J. Hanley, Karthik Venkatakrishnan, et al.. (2018). Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces. Cancer Chemotherapy and Pharmacology. 82(5). 803–814. 6 indexed citations

12.

Gupta, Neeraj, Paul M. Diderichsen, Michael J. Hanley, et al.. (2017). Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clinical Pharmacokinetics. 56(11). 1355–1368. 39 indexed citations

13.

Gupta, Neeraj, Huyuan Yang, Michael J. Hanley, et al.. (2017). Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology. 12(5). 643–654. 16 indexed citations

14.

Gupta, Neeraj, Yeow Tee Goh, Chang‐Ki Min, et al.. (2015). Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. Journal of Hematology & Oncology. 8(1). 103–103. 33 indexed citations

15.

Hagspiel, Klaus D., Lucía Flors, Michael J. Hanley, & Patrick T. Norton. (2014). Computed Tomography Angiography and Magnetic Resonance Angiography Imaging of the Mesenteric Vasculature. Techniques in vascular and interventional radiology. 18(1). 2–13. 50 indexed citations

16.

Hanley, Michael J., Dimitrios Mitsouras, Michael L. Steigner, et al.. (2013). Computed Tomography Angiography Gravitational Gradient as an Imaging Sign of Slow Flow. Journal of Computer Assisted Tomography. 37(2). 297–300. 3 indexed citations

17.

Gupta, Neeraj, Karthik Venkatakrishnan, Dennis A. Noe, et al.. (2013). A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma.. Journal of Clinical Oncology. 31(15_suppl). 2555–2555. 3 indexed citations

18.

Ramos-Duran, Luis, et al.. (2010). Current Contrast Media Delivery Strategies for Cardiac and Pulmonary Multidetector-row Computed Tomography Angiography. Journal of Thoracic Imaging. 25(4). 270–277. 19 indexed citations

19.

Hanley, Michael J., Nicholas M. P. King, & David J. Greenblatt. (2010). Effect of Obesity on the Pharmacokinetics of Drugs in Humans. Clinical Pharmacokinetics. 49(2). 71–87. 557 indexed citations breakdown →

20.

Ahmadibeni, Yousef, Chandravanu Dash, Michael J. Hanley, et al.. (2010). Synthesis of nucleoside 5′-O-α,β-methylene-β-triphosphates and evaluation of their potency towards inhibition of HIV-1 reverse transcriptase. Organic & Biomolecular Chemistry. 8(6). 1271–1271. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact